CCIA
HRMY icon

Campbell & Co Investment Adviser’s Harmony Biosciences HRMY Stock Holding History

Campbell & Co Investment Adviser’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,938
Closed -$222K – 1182
2026
Q1 		$222K Sell
7,938
-14,158
-64% -$464K 0.01% 949
2025
Q4 		$827K Sell
22,096
-6,775
-23% -$223K 0.04% 635
2025
Q3 		$796K Sell
28,871
-16,036
-36% -$552K 0.06% 516
2025
Q2 		$1.42M Buy
44,907
+31,210
+228% +$1M 0.09% 362
2025
Q1 		$455K Sell
13,697
-6,654
-33% -$239K 0.03% 722
2024
Q4 		$700K Sell
20,351
-18,745
-48% -$644K 0.05% 533
2024
Q3 		$1.56M Buy
39,096
+23,049
+144% +$810K 0.12% 263
2024
Q2 		$484K Sell
16,047
-10,019
-38% -$301K 0.04% 667
2024
Q1 		$875K Buy
26,066
+10,510
+68% +$337K 0.08% 457
2023
Q4 		$502K Buy
15,556
+2,953
+23% +$82.4K 0.05% 712
2023
Q3 		$413K Buy
+12,603
New +$438K 0.05% 601

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell & Co Investment Adviser's HRMY Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 7,938 shares — an estimated $222K sold.

Campbell & Co Investment Adviser first reported a position in HRMY in Q3 2023 and held it in 11 quarters. The position peaked at $1.56M in Q3 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 7,938 Harmony Biosciences shares in Q2 2026, an estimated $222K.
  • Campbell & Co Investment Adviser first reported a position in Harmony Biosciences in Q3 2023 and held it in 11 quarters.
  • Campbell & Co Investment Adviser's Harmony Biosciences position peaked at $1.56M in Q3 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.